首页> 外文期刊>Journal of liposome research >Plasma, blood and liver tissue sample preparation methods for the separate quantification of liposomal-encapsulated prednisolone phosphate and non-encapsulated prednisolone
【24h】

Plasma, blood and liver tissue sample preparation methods for the separate quantification of liposomal-encapsulated prednisolone phosphate and non-encapsulated prednisolone

机译:血浆,血液和肝组织样品制备方法,用于单独定量脂质体包封的泼尼松酮磷酸盐和非包封的泼尼松龙

获取原文
获取原文并翻译 | 示例
           

摘要

Besides the development of sample preparation methods for the determination of separate liposomal-encapsulated prednisolone phosphate and non-encapsulated prednisolone concentrations in murine plasma and blood, this article also presents the first description of an accurate sample preparation method for the determination of such separate concentrations in the murine liver. The quantitative differentiation is based on the immediate hydrolysis of prednisolone phosphate (PP) into prednisolone (P) after its release from the liposomes in vivo: PP represents the encapsulated drug, while P represents the non-encapsulated drug. The use of 10 ml methanol/g tissue during homogenization of liver tissue ensures complete liposome rupture, prevention of the dephosphorylation of PP released during homogenization, sufficient clean supernatants, excellent extraction of P and sufficient extraction of PP and excellent accuracies and precision complying with the internal guidelines for pre-clinical studies (80-120% and maximal 20%, respectively). Similarly, the matching sample preparation methods for plasma and blood involve protein precipitation with four equivalents of methanol also ensuring accuracies and precision complying with the internal guidelines for pre-clinical studies. Application of these sample preparation methods is going to generate the first pharmacokinetic (PK) profile of a liposomal preparation, in which the encapsulated and non-encapsulated drug concentrations in a tissue are measured separately. Such separated concentration profiles can gain important insights into the PKs of liposomal PP and probably also with regard to liposomal formulations in general, like the quantification of the in vivo drug release from the liposomes.
机译:除了在测定单独的脂质体包封的泼尼松酮磷酸盐和鼠血浆中的非包裹的泼尼松酮浓度的样品制备方法之外,本文还介绍了用于测定这种单独浓度的准确样品制备方法的首先描述小鼠肝脏。定量分化基于在体内脂质体释放后的泼尼松酮磷酸酯(PP)的直接水解在体内的脂质体中:PP代表包封的药物,而P代表非包封的药物。在肝脏组织均化过程中使用10ml甲醇/ g组织确保完全脂质体破裂,预防均质化,足够清洁的上清液,PP优异提取的PP释放的去磷酸化,并充分提取PP和优异的精度和精确的精度和精度遵守致力临床前研究的内部准则(分别为80-120%和最大20%)。类似地,血浆和血液的匹配样品制备方法涉及蛋白质沉淀,具有四当量的甲醇,也确保了符合临床前研究的内部准则的准确性和精度。这些样品制备方法的应用将产生脂质体制剂的第一药代动力学(PK)型材,其中组织中包封和未包封的药物浓度分别测量。这种分离的浓度曲线可以在脂质体PP的PKS中获得重要的见解,并且通常还关于脂质体制剂,如将来自脂质体的体内药物释放的量化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号